Insider · CIK 0001530968
Karen L. Zaderej
Files at AXGN (Axogen, Inc.), EYPT (EyePoint Pharmaceuticals, Inc.). First filing Mar 25, 2024, latest Aug 18, 2026.
In brief
Karen L. Zaderej files SEC Form 4 as director and CEO at EYPT (EyePoint Pharmaceuticals, Inc.), and also at AXGN (Axogen, Inc.). Since Mar 25, 2024, Karen L. Zaderej has reported 3 open-market buys worth $166k and 1 open-market sell worth $302k, the latest filed on Aug 18, 2026.
A track record needs three past buys with six months of prices behind them; Karen L. Zaderej has 2, so none is measured yet.
The newest scored trade: bought $52k of EYPT on Aug 18, 2026, filed Aug 18, 2026, scored 36 (weak). In the last 12 months: 1 buy worth $52k and 0 sells worth $0.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
EYPT: EyePoint Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
AXGN: Axogen, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | EYPTbuy EyePoint Pharmaceuticals, Inc. | $52k 10,600 shares | +28% | +12% from low-71% from high | |
| 33Weak | EYPTbuy EyePoint Pharmaceuticals, Inc. | $59k 10,000 shares | +38% | - | |
| 32Weak | EYPTbuy EyePoint Pharmaceuticals, Inc. | $54k 10,000 shares | +61% | - | |
| 39Weak | Axogen, Inc. | $302k 39,280 shares | -3% | +112% from low-28% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 21, 2025 | AXGN Axogen, Inc. | 220,000 0.50% of outstanding | $4.0M | Jan 21, 2025 | $2.7M |
| Jan 14, 2025 | AXGN Axogen, Inc. | 100,000 0.23% of outstanding | $1.8M | Jan 14, 2025 | $907k |
| Nov 7, 2024 | AXGN Axogen, Inc. | 70,000 0.16% of outstanding | $890k | Nov 7, 2024 | $4.2M |
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | EYPT EyePoint Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +10,600 | $4.93 | $52k | 49,100 | Aug 18, 2026 |
| Jan 2, 2026 | EYPT EyePoint Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jan 6, 2026 |
| Jul 11, 2025 | EYPT EyePoint Pharmaceuticals, Inc. | MOption exercise Common Stock | +2,000 | $0.00 | $0 | 38,500 | Jul 11, 2025 |
| Jul 11, 2025 | EYPT EyePoint Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -2,000 | $0.00 | $0 | 0 | Jul 11, 2025 |
| May 16, 2025 | EYPT EyePoint Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +5,000 | $5.81 | $29k | 31,500 | May 19, 2025 |
| May 19, 2025 | EYPT EyePoint Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +5,000 | $5.99 | $30k | 36,500 | May 19, 2025 |
| May 14, 2025 | EYPT EyePoint Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +5,000 | $5.42 | $27k | 21,500 | May 15, 2025 |
| May 15, 2025 | EYPT EyePoint Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +5,000 | $5.47 | $27k | 26,500 | May 15, 2025 |
| Jan 3, 2025 | EYPT EyePoint Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jan 7, 2025 |
| Mar 16, 2024 | AXGN Axogen, Inc. | MOption exercise Common Stock | +84,847 | $0.00 | $0 | 1,157,593 | Mar 25, 2024 |
| Mar 21, 2024 | AXGN Axogen, Inc. | SOpen-market sale Common Stock | -33,028 | $7.68 | $254k | 1,124,565 | Mar 25, 2024 |
| Mar 16, 2024 | AXGN Axogen, Inc. | MOption exercise Common Stock | +12,500 | $0.00 | $0 | 1,137,065 | Mar 25, 2024 |
| Mar 21, 2024 | AXGN Axogen, Inc. | SOpen-market sale Common Stock | -3,086 | $7.68 | $24k | 1,133,979 | Mar 25, 2024 |
| Mar 16, 2024 | AXGN Axogen, Inc. | MOption exercise Common Stock | +12,975 | $0.00 | $0 | 1,146,954 | Mar 25, 2024 |
| Mar 21, 2024 | AXGN Axogen, Inc. | SOpen-market sale Common Stock | -3,166 | $7.68 | $24k | 1,143,788 | Mar 25, 2024 |
| Mar 16, 2024 | AXGN Axogen, Inc. | MOption exercise Restricted Stock Unitsderivative | -84,847 | $0.00 | $0 | 84,847 | Mar 25, 2024 |
| Mar 16, 2024 | AXGN Axogen, Inc. | MOption exercise Restricted Stock Unitsderivative | -12,500 | $0.00 | $0 | 12,500 | Mar 25, 2024 |
| Mar 16, 2024 | AXGN Axogen, Inc. | MOption exercise Restricted Stock Unitsderivative | -12,975 | $0.00 | $0 | 0 | Mar 25, 2024 |
| Jan 5, 2024 | EYPT EyePoint Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +25,014 | $0.00 | $0 | 25,014 | Jan 9, 2024 |
| Jul 18, 2023 | AXGN Axogen, Inc. | AGrant or award Common Stock | +22,076 | $0.00 | $0 | 1,072,746 | Oct 13, 2023 |
Questions about Karen L. Zaderej
Answered from the filings on this page, as of the latest one.
Is Karen L. Zaderej buying or selling?
In the last 12 months Karen L. Zaderej reported 1 open-market buy worth $52k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $52k of EYPT on Aug 18, 2026. Grants, option exercises and tax withholding are not counted.
How did Karen L. Zaderej's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Karen L. Zaderej has 2.
Where does Karen L. Zaderej file Form 4?
Karen L. Zaderej has filed Form 4 at EYPT (EyePoint Pharmaceuticals, Inc.); AXGN (Axogen, Inc.) as CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.